Skip to content

All Episodes – Page 7

Browse our complete library of interviews and discussions with leading experts in oncology.

Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy

Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy

An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon

10 June 2025
7 min
Patients with Relapsed or Refractory Acute Myeloid Leukemia have Remissions with “Logic Gated”  Off-the-Shelf Natural Killer Cell Therapy

Patients with Relapsed or Refractory Acute Myeloid Leukemia have Remissions with “Logic Gated”  Off-the-Shelf Natural Killer Cell Therapy

An Interview with: Stephen Strickland, Jr. MD MSCI, Director, Leukemia Research; Executive Chair, Leukemia Research Committee, Sarah Cannon Research Instiute, Nashville, Tennessee USA CHICAGO – Severa

8 May 2025
14 min
More Breast Cancer Cases in Younger Women since 2010 But Fewer Deaths

More Breast Cancer Cases in Younger Women since 2010 But Fewer Deaths

An interview with: Adetunji T. Toriola, MD, PhD, MPH, Professor of Surgery, Department of Surgery and Division of Public Health Sciences, Washington University School of Medicine and Siteman Cancer Ce

7 May 2025
15 min
Fast, Accurate Artificial Intelligence Method to Diagnose and Classify Pediatric Sarcoma Anywhere

Fast, Accurate Artificial Intelligence Method to Diagnose and Classify Pediatric Sarcoma Anywhere

An interview with: Adam Thiesen, PhD Candidate, UConn Health, University of Connecticut and the Jackson Laboratory for Genomic Medicine, Farmington,  CT And with: Jayesh Desai MD, Medical Oncologist,

6 May 2025
16 min
EGFR-Sparing Anti-HER2 Drug Benefits Patients with Advanced HER2-Mutated Non-Small Cell Lung Cancer

EGFR-Sparing Anti-HER2 Drug Benefits Patients with Advanced HER2-Mutated Non-Small Cell Lung Cancer

An interview with: John V Heymach MD PhD, Professor and Chair of Thoracic/Head and Neck Medical Oncology, Ruth Legett Jones Distinguished Chair, University of Texas MD Anderson Cancer Center, Houston

4 May 2025
13 min
Neoadjuvant PD-1 Blockade Enables Patients with Mismatch Repair Deficient Colorectal Cancers to Avoid Surgery

Neoadjuvant PD-1 Blockade Enables Patients with Mismatch Repair Deficient Colorectal Cancers to Avoid Surgery

An interview with: Andrea Cercek MD, Gastrointestinal Cancer Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York And: Ryan B Corcoran MD PhD, Director of the GI Cancer Program, Massac

3 May 2025
14 min
Topical BRAF-inhibiting Gel Controls Acneiform Rash in Patients with Colorectal Cancer Treated with EGFR-inhibition

Topical BRAF-inhibiting Gel Controls Acneiform Rash in Patients with Colorectal Cancer Treated with EGFR-inhibition

An interview with: Anisha B Patel MD, Associate Professor of Dermatology, Division of Internal Medicine, MD Anderson Cancer Center, Houston TX CHICAGO, USA—Acneiform rash toxicities caused by anti- ep

2 May 2025
9 min
RAS Inhibitor Zoldonrasib Brings Clinical Benefit in Patients with G12D Mutated Non-Small Cell Advanced Lung Cancer

RAS Inhibitor Zoldonrasib Brings Clinical Benefit in Patients with G12D Mutated Non-Small Cell Advanced Lung Cancer

An interview with: Kathryn C Arbour MD, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York USA And: Ryan B Corcoran MD PhD, Massachusetts General Cancer Center, Associate Pr

30 April 2025
12 min
Two Checkpoint Inhibitors in One Bispecific Molecule Improved Survival in Patients with High-Risk Gastric Cancer

Two Checkpoint Inhibitors in One Bispecific Molecule Improved Survival in Patients with High-Risk Gastric Cancer

An interview with: Jiafu Ji MD PhD DrPH FRCS, Fellow of the Chinese Academy of Medical Science, Professor and Chief, Gastrointestinal Cancer Center, Peking University Cancer Hospital, Beijing Institut

23 April 2025
10 min
Exosome Liquid Biopsy for Earliest Pancreatic Cancer Detection

Exosome Liquid Biopsy for Earliest Pancreatic Cancer Detection

An interview with: Ajay Goel PhD, Chair of the Molecular Diagnostics and Experimental Therapeutics Department, Beckman Research Institute, City of Hope, Los Angeles California.  SAN DIEGO—The prospect

10 April 2025
13 min
Long Remissions with Bispecific T-cell Engager Antibody Therapy for Patients with Relapsed Multiple Myeloma

Long Remissions with Bispecific T-cell Engager Antibody Therapy for Patients with Relapsed Multiple Myeloma

An interview with: Sundar Jagannath MBBS, Professor of Medicine, Hematology and Medical Oncology, Director of the Center of Excellence for Multiple Myeloma, Icahn School of Medicine, Mount Sinai, New

9 April 2025
16 min
Olivier Lantz MD PhD; AACR 2024: Personalized Vaccine Brought Durable Immune Responses and Fewer Relapses in Head and Neck Cancers

Olivier Lantz MD PhD; AACR 2024: Personalized Vaccine Brought Durable Immune Responses and Fewer Relapses in Head and Neck Cancers

An interview with: Olivier Lantz MD PhD, Head of the Clinical Immunology Laboratory, Institut Curie, Paris, France PARIS, France—A clinical trial using a personalized therapeutic vaccine, that

9 April 2025
14 min
Adding Anthracycline Improved Outcomes for Patients with High-Risk HR-positive, HER2-negative Breast Cancer

Adding Anthracycline Improved Outcomes for Patients with High-Risk HR-positive, HER2-negative Breast Cancer

SAN ANTONIO, USA—Women with hormone receptor positive HER-2 negative breast cancer and Oncotype DX recurrence scores above 31 could benefit from having anthracycline therapy added to their taxane-base

28 March 2025
8 min
Specific Subgroups of Patients with Metastatic Castration Resistant Prostate Cancer Live Longer with Talazoparib Added to their Enzalutamide Therapy

Specific Subgroups of Patients with Metastatic Castration Resistant Prostate Cancer Live Longer with Talazoparib Added to their Enzalutamide Therapy

SAN FRANCISCO, CA—Adding the poly ADP ribose polymerase (PARP) inhibitor drug talazoparib to standard anti-androgen therapy with enzalutamide statistically significantly extended overall survival amon

13 March 2025
22 min
Patients with Desmoplastic Melanoma Were Exceptional Responders to Single Agent Pembrolizumab

Patients with Desmoplastic Melanoma Were Exceptional Responders to Single Agent Pembrolizumab

Audio Journal of Oncology Patients with Desmoplastic Melanoma Were Exceptional Responders to Single Agent Pembrolizumab LOS ANGELES, CA—Single agent immunotherapy with the anti-programmed death-1 (PD-

11 March 2025
14 min
Bilateral Mastectomy and Salpingo-Oophorectomy Significantly Extend Survival In BRCA-mutation Carriers Who Already Have Breast Cancer

Bilateral Mastectomy and Salpingo-Oophorectomy Significantly Extend Survival In BRCA-mutation Carriers Who Already Have Breast Cancer

Bilateral Mastectomy and Salpingo-Oophorectomy Significantly Extend Survival In BRCA-mutation Carriers Who Already Have Breast Cancer The important question of whether to recommend risk-reducing surge

26 February 2025
13 min
E. Shelley Hwang MD MPH: Randomized Study Found Surgery-Sparing Active Monitoring Safe in Patients With Low-risk DCIS

E. Shelley Hwang MD MPH: Randomized Study Found Surgery-Sparing Active Monitoring Safe in Patients With Low-risk DCIS

SAN ANTONIO, USA—In patients with hormone receptor-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS) active monitoring, compared with surgery, resulted in no difference in terms of can

16 January 2025
14 min